RESUMO
INTRODUCTION: Current evidence supports a vital role of the microbiota on health outcomes, with alterations in an otherwise healthy balance linked to chronic medical conditions like celiac disease (CD). Recent advances in microbiome analysis allow for unparalleled profiling of the microbes and metabolites. With the growing volume of data available, trends are emerging that support a role for the gut microbiota in CD pathogenesis. AREAS COVERED: In this article, the authors review the relationship between factors such as genes and antibiotic exposure on CD onset and the intestinal microbiota. The authors also review other microbiota within the human body (like the oropharynx) that may play a role in CD pathogenesis. Finally, the authors discuss implications for disease modification and the ultimate goal of prevention. The authors reviewed literature from PubMed, EMBASE, and Web of Science. EXPERT OPINION: CD serves as a unique opportunity to explore the role of the intestinal microbiota on the development of chronic autoimmune disease. While research to date provides a solid foundation, most studies have been case-control and thus do not have capacity to explore the mechanistic role of the microbiota in CD onset. Further longitudinal studies and integrated multi-omics are necessary for investigating CD pathogenesis.
Assuntos
Doença Celíaca/microbiologia , Microbioma Gastrointestinal/imunologia , Animais , Antibacterianos/efeitos adversos , Doença Celíaca/metabolismo , Doença Celíaca/terapia , Disbiose , Interação Gene-Ambiente , Interações entre Hospedeiro e Microrganismos , Humanos , Transdução de SinaisRESUMO
Although celiac disease (CD) is an autoimmune disease that primarily involves the intestinal tract, mounting evidence suggests that a sizeable number of patients exhibit neurological deficits. About 40% of the celiac patients with neurological manifestations have circulating antibodies against neural tissue transglutaminase-6 (tTG6). While early diagnosis and strict adherence to a gluten-free diet (GFD) have been recommended to prevent neurological dysfunction, better therapeutic strategies are needed to improve the overall quality of life. Dysregulation of the microbiota-gut-brain axis, presence of anti-tTG6 antibodies, and epigenetic mechanisms have been implicated in the pathogenesis. It is also possible that circulating or gut-derived extracellular structures and including biomolecular condensates and extracellular vesicles contribute to disease pathogenesis. There are several avenues for shaping the dysregulated gut homeostasis in individuals with CD, non-celiac gluten sensitivity (NCGS) and/or neurodegeneration. In addition to GFD and probiotics, nutraceuticals, such as phyto and synthetic cannabinoids, represent a new approach that could shape the host microbiome towards better prognostic outcomes. Finally, we provide a data-driven rationale for potential future pre-clinical research involving non-human primates (NHPs) to investigate the effect of nutraceuticals, such as phyto and synthetic cannabinoids, either alone or in combination with GFD to prevent/mitigate dietary gluten-induced neurodegeneration.
Assuntos
Canabinoides/uso terapêutico , Doença Celíaca/terapia , Dieta Livre de Glúten/métodos , Disbiose/terapia , Doenças Neurodegenerativas/prevenção & controle , Probióticos/uso terapêutico , Autoanticorpos/sangue , Doença Celíaca/diagnóstico , Doença Celíaca/imunologia , Doença Celíaca/microbiologia , Suplementos Nutricionais , Disbiose/diagnóstico , Disbiose/imunologia , Disbiose/microbiologia , Diagnóstico Precoce , Epigênese Genética , Vesículas Extracelulares/química , Vesículas Extracelulares/metabolismo , Microbioma Gastrointestinal/efeitos dos fármacos , Glutens/efeitos adversos , Humanos , Doenças Neurodegenerativas/diagnóstico , Doenças Neurodegenerativas/imunologia , Doenças Neurodegenerativas/microbiologia , Proteína 2 Glutamina gama-Glutamiltransferase , Qualidade de Vida , Transglutaminases/antagonistas & inibidores , Transglutaminases/genética , Transglutaminases/imunologiaRESUMO
Celiac disease (CD) is associated with intestinal microbiota alterations. The administration of prebiotics could be a promising method of restoring gut homeostasis in CD. The aim of this study was to evaluate the effect of prolonged oligofructose-enriched inulin (Synergy 1) administration on the characteristics and metabolism of intestinal microbiota in CD children following a gluten-free diet (GFD). Thirty-four paediatric CD patients (mean age 10 years; 62% females) on a GFD were randomized into two experimental groups receiving Synergy 1 (10 g/day) or placebo (maltodextrin; 7 g/day) for 3 months. The quantitative gut microbiota characteristics and short-chain fatty acids (SCFAs) concentration were analysed. In addition, side effects were monitored. Generally, the administration of Synergy 1 in a GFD did not cause any side effects. After the intervention period, Bifidobacterium count increased significantly (p < 0.05) in the Synergy 1 group. Moreover, an increase in faecal acetate and butyrate levels was observed in the prebiotic group. Consequently, total SCFA levels were 31% higher than at the baseline. The presented trial shows that Synergy 1 applied as a supplement of a GFD had a moderate effect on the qualitative characteristics of faecal microbiota, whereas it stimulated the bacterial metabolite production in CD children.
Assuntos
Doença Celíaca/terapia , Dieta Livre de Glúten , Disbiose/tratamento farmacológico , Ácidos Graxos Voláteis/metabolismo , Microbioma Gastrointestinal/efeitos dos fármacos , Inulina/uso terapêutico , Oligossacarídeos/farmacologia , Ácido Acético/metabolismo , Adolescente , Carga Bacteriana/efeitos dos fármacos , Bifidobacterium/efeitos dos fármacos , Bifidobacterium/crescimento & desenvolvimento , Bifidobacterium/metabolismo , Ácido Butírico/metabolismo , Doença Celíaca/complicações , Doença Celíaca/metabolismo , Doença Celíaca/microbiologia , Criança , Pré-Escolar , Disbiose/etiologia , Disbiose/metabolismo , Fezes/química , Fezes/microbiologia , Feminino , Humanos , Mucosa Intestinal/metabolismo , Intestinos/efeitos dos fármacos , Intestinos/microbiologia , Inulina/farmacologia , Masculino , PrebióticosRESUMO
ABSTRACT BACKGROUND Healthy individuals exhibit a significantly higher concentration of faecal bifidobacteria in comparison to celiac patients. Even though there are potential benefits in probiotic usage, they have been little explored as an adjunctive therapy in celiac disease. OBJECTIVE This study aimed at the comparison of faecal bifidobacteria concentration and pH among celiac patients and healthy subjects before and after the daily intake of 100 g of yogurt containing probiotic for a thirty-day period. METHODS Feces from 17 healthy subjects and 14 celiac patients were analyzed, in which stool culture was performed for the isolation and quantification of faecal bifidobacteria. Furthermore, Gram’s method was employed for the microscopic analysis of the colonies, while the identification of the Bifidobacterium genus was made through determination of the fructose-6-phosphate phosphoketolase enzyme. Faecal pH was measured using a calibrated pHmeter. RESULTS Faecal bifidobacteria concentration before probiotic consumption was significantly higher in healthy individuals (2.3x108±6.3x107 CFU/g) when compared to celiac patients (1.0x107±1.7x107 CFU/g). Faecal pH values did not show a significant difference. After the daily consumption of probiotic-containing yogurt both groups showed a significant increase in the concentration of faecal bifidobacteria, but healthy subjects presented significantly higher bifidobacteria concentrations (14.7x108±0.2x108 CFU/g) than the celiac group (0.76x108±0.1x108 CFU/g). The obtained pH values from both groups were not significantly different, being 7.28±0.518 for the celiac patients and 7.07±0.570 for healthy individuals after the probiotic intake. CONCLUSION The probiotic supplementation significantly increased the number of bifidobacteria in the feces of celiac patients, although it was not sufficient to reach the concentration found in healthy individuals prior to its consumption.
RESUMO CONTEXTO Indivíduos saudáveis apresentam uma concentração de bifidobactérias fecais significativamente maior em comparação a pacientes celíacos. Apesar de haver benefícios potenciais no uso de probióticos na doença celíaca, estes têm sido pouco explorados como uma terapia adjuvante. OBJETIVO Este estudo objetivou a comparação do pH e concentração fecal de bifidobactérias entre pacientes celíacos e indivíduos saudáveis antes e após o consumo diário de 100 g de iogurte contendo probiótico por um período de 30 dias. MÉTODOS Foram analisadas fezes de 17 pessoas saudáveis e 14 pacientes celíacos, tendo sido realizada a coprocultura para o isolamento e quantificação de bifidobactérias fecais. Além disso, o método de Gram foi empregado na análise microscópica das colônias, enquanto a identificação do gênero Bifidobacterium foi feita através da determinação da enzima frutose-6-fosfato fosfocetolase. O pH fecal foi medido usando um pHmetro calibrado. RESULTADOS A concentração de bifidobactérias fecais antes do consumo do iogurte probiótico foi significativamente maior em indivíduos saudáveis (2.3x108±6.3x107 UFC/g) quando comparada aos celíacos (1.0x107±1.7x107 CFU/g). Por outro lado, o pH fecal de ambos os grupos não apresentou diferença significativa. Após o consumo diário de iogurte contendo probiótico, ambos os grupos tiveram um aumento significativo na concentração de bifidobactérias fecais, entretanto indivíduos saudáveis apresentaram concentrações de bifidobactérias significativamente maiores (14.7x108±0.2x108 UFC/g) do que o grupo celíaco (0.76x108±0.1x108 UFC/g). Os valores de pH obtidos de ambos os grupos não foram significativamente diferentes, sendo de 7.28±0.518 para os pacientes celíacos e de 7.07±0.570 para os indivíduos saudáveis após o consumo do probiótico. CONCLUSÃO A suplementação com probiótico aumentou significativamente o número de bifidobactérias nas fezes dos pacientes celíacos apesar de não ter sido suficiente para alcançar a concentração encontrada em indivíduos saudáveis antes do consumo de probióticos.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Adulto Jovem , Iogurte , Bifidobacterium/crescimento & desenvolvimento , Doença Celíaca/tratamento farmacológico , Probióticos/administração & dosagem , Suplementos Nutricionais , Contagem de Colônia Microbiana , Doença Celíaca/microbiologia , Fezes/microbiologia , Fezes/química , Concentração de Íons de Hidrogênio , Pessoa de Meia-IdadeRESUMO
BACKGROUND: Healthy individuals exhibit a significantly higher concentration of faecal bifidobacteria in comparison to celiac patients. Even though there are potential benefits in probiotic usage, they have been little explored as an adjunctive therapy in celiac disease. OBJECTIVE: This study aimed at the comparison of faecal bifidobacteria concentration and pH among celiac patients and healthy subjects before and after the daily intake of 100 g of yogurt containing probiotic for a thirty-day period. METHODS: Feces from 17 healthy subjects and 14 celiac patients were analyzed, in which stool culture was performed for the isolation and quantification of faecal bifidobacteria. Furthermore, Gram's method was employed for the microscopic analysis of the colonies, while the identification of the Bifidobacterium genus was made through determination of the fructose-6-phosphate phosphoketolase enzyme. Faecal pH was measured using a calibrated pHmeter. RESULTS: Faecal bifidobacteria concentration before probiotic consumption was significantly higher in healthy individuals (2.3x108±6.3x107 CFU/g) when compared to celiac patients (1.0x107±1.7x107 CFU/g). Faecal pH values did not show a significant difference. After the daily consumption of probiotic-containing yogurt both groups showed a significant increase in the concentration of faecal bifidobacteria, but healthy subjects presented significantly higher bifidobacteria concentrations (14.7x108±0.2x108 CFU/g) than the celiac group (0.76x108±0.1x108 CFU/g). The obtained pH values from both groups were not significantly different, being 7.28±0.518 for the celiac patients and 7.07±0.570 for healthy individuals after the probiotic intake. CONCLUSION: The probiotic supplementation significantly increased the number of bifidobacteria in the feces of celiac patients, although it was not sufficient to reach the concentration found in healthy individuals prior to its consumption.
Assuntos
Bifidobacterium/crescimento & desenvolvimento , Doença Celíaca/dietoterapia , Suplementos Nutricionais , Probióticos/administração & dosagem , Iogurte , Adolescente , Adulto , Doença Celíaca/microbiologia , Contagem de Colônia Microbiana , Fezes/química , Fezes/microbiologia , Feminino , Humanos , Concentração de Íons de Hidrogênio , Masculino , Pessoa de Meia-Idade , Adulto JovemRESUMO
Coeliac disease (CD) is associated with alterations of the intestinal microbiota. Although several Bifidobacterium strains showed anti-inflammatory activity and prevention of toxic gliadin peptides generation in vitro, few data are available on their efficacy when administered to CD subjects. This study evaluated the effect of administration for three months of a food supplement based on two Bifidobacterium breve strains (B632 and BR03) to restore the gut microbial balance in coeliac children on a gluten free diet (GFD). Microbial DNA was extracted from faeces of 40 coeliac children before and after probiotic or placebo administration and 16 healthy children (Control group). Sequencing of the amplified V3-V4 hypervariable region of 16S rRNA gene as well as qPCR of Bidobacterium spp., Lactobacillus spp., Bacteroides fragilis group Clostridiumsensu stricto and enterobacteria were performed. The comparison between CD subjects and Control group revealed an alteration in the intestinal microbial composition of coeliacs mainly characterized by a reduction of the Firmicutes/Bacteroidetes ratio, of Actinobacteria and Euryarchaeota. Regarding the effects of the probiotic, an increase of Actinobacteria was found as well as a re-establishment of the physiological Firmicutes/Bacteroidetes ratio. Therefore, a three-month administration of B. breve strains helps in restoring the healthy percentage of main microbial components.
Assuntos
Bifidobacterium breve , Doença Celíaca/terapia , Suplementos Nutricionais , Microbioma Gastrointestinal/fisiologia , Probióticos/administração & dosagem , Actinobacteria , Adolescente , Bacteroidetes , Doença Celíaca/microbiologia , Criança , Pré-Escolar , Terapia Combinada , DNA Bacteriano/análise , Dieta Livre de Glúten , Método Duplo-Cego , Fezes/microbiologia , Feminino , Firmicutes , Humanos , Lactente , Masculino , Projetos Piloto , RNA Ribossômico 16S/análise , Adulto JovemRESUMO
Metabolomics is the emerging science of measurement and analysis of metabolome--the complete set of low molecular weight compounds in a cell, tissue, organ or whole organism. One of the aims of metabolomics is to research the response of an organism to a pathophysiological insult by measuring the concentrations of small molecule metabolites in biofluids and tissues and its dynamics. Intestinal microbiota is most probably involved in the development and maintenance of autoimmune inflammation in ulcerative colitis and celiac disease. Gas chromatography-mass spectrometry (GC - MS) of serum generates comprehensive metabolic profiles, reflecting integrated human (systemic) and gut microbial metabolism which may be altered in disease states. The aim of this study was to investigate GC - MS-based serum metabolomic profiles in UC and CD patients. Serum metabolic profiles were collected from 75 individuals: 20 patients with mild-moderate active UC, 35 CD patients, and 20 healthy controls (HC). We characterized 84 serum metabolites by use GC-MS. 18 metabolites at least have a combined (human + microbial) origin. In serum of UC patients, phenylacetic acid (PAA), 4-hydroxyphenylacetic acid (4-HPAA), 3-indolylacetic acid (IAA), succinic acid (SA) and fumaric acid (FA) were the metabolites most prominently increased, whereas 3-phenylpropionic acid (PPA) was significantly decreased. Serum of CD patients showed significant increases in IAA, 3-indolepropionic acid (IPA), SA and FA. Increased serum levels of succinic acid suggest its possible damaging effect on intestinal mucosa especially in ulcerative colitis. Orally administered butyrate + inulin as supplement to mesalazine in UC or gluten free diet in CD was effective in reducing disease activity with a marked improvement of serum metabolomic profiles (including SA reduction) and gut microbiota in both diseases. There were no any adverse events.